Aristeia Capital L.L.C. Purchases New Shares in Hologic, Inc. $HOLX

Key Points

• Aristeia Capital L.L.C. has acquired a new position in Hologic, Inc., purchasing 4,544 shares valued at approximately $281,000 during the first quarter.
• Several hedge funds have also made moves towards Hologic, with institutional investors owning 94.73% of the company’s stock.
• Analysts have a consensus rating of Moderate Buy for Hologic, with a price target averaging around $78.00.

Aristeia Capital L.L.C. acquired a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 4,544 shares of the medical equipment provider's stock, valued at approximately $281,000.

A number of other hedge funds also recently modified their holdings of HOLX. Zions Bancorporation National Association UT bought a new stake in shares of Hologic in the 1st quarter worth approximately $34,000. Allworth Financial LP lifted its position in shares of Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Hologic in the 1st quarter worth approximately $42,000. Larson Financial Group LLC lifted its position in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 722 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in shares of Hologic in the 4th quarter worth approximately $49,000. Institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on HOLX. Evercore ISI raised their price objective on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Argus upgraded Hologic from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, August 18th. Morgan Stanley raised their price objective on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Royal Bank Of Canada upgraded Hologic from a "sector perform" rating to an "outperform" rating and raised their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. Finally, UBS Group raised their target price on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $78.00.

Hologic Price Performance

Shares of Hologic stock traded down $1.93 during midday trading on Friday, hitting $64.45. 1,005,460 shares of the company were exchanged, compared to its average volume of 1,330,759. The firm has a 50 day simple moving average of $66.43 and a 200-day simple moving average of $62.64. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The firm has a market cap of $14.33 billion, a P/E ratio of 26.74, a PEG ratio of 2.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same period last year, the firm posted $1.06 EPS. The business's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.